Posters

Two faces of herpetic keratitis today: clinical and laboratory

Poster Details

First Author: G.Chernakova RUSSIA

Co Author(s):                        

Abstract Details

Purpose:

to evaluate modern data concerning clinical features and viral production by PCR in patients with herpetic keratitis

Setting:

Lack of knowledge concerning aspects of clinical manifestation - on one hand and viral production in biological fluids by herpetic keratitis - on the other -  leads to invalid diagnosis and inadequate therapy course

Methods:

Thorough anamnesis survey, especially concerning comorbidity, trigger factors and history of herpes simplex (labialis, nasalis, genitalis) was conducted in 75 patients with different clinical forms of herpetic keratitis. 4 biological fluids (tear, saliva, serum, urine) were investigated by PCR for HSV, VVZ, CMV, EBV, HHV-6, HHV-7 before and after treatment based on systemic nucleoside analogues (control group was presented by 10 healthy individuals).

Results:

Two groups of comorbid diseases  predominated - inflammatory diseases of nasopharynx and upper respiratory tract and endocrinological disorders (diabetes mellites).  Significant role in keratitis development is played by chronic long-term xerosis (due to ofthalmosurgery, blepharoplasty, prostaglandin analogs instillation, etc). Among trigger factors the leading positions are occupied by acute corneal trauma, acute respiratory infections and common cold, and by some rather new - dental implantation, nasal septoplasty, Botox injections. Herpetic viral activity  in 4 media displays DNA production of all above mentioned herpesviruses (including unexpected  VVZ,CMV, HHV-6, HHV-7) much more experessed in saliva and urine then in tear and serum.

Conclusions:

Herpetic keratitis is thought to be a result of long-term process of subclinical viral production, prepared and  influenced by comorbidity and  trigged one day by stimulating factor. Herpetic keratitis might be considered as a "polyherpetic" diseases, associated by systemic viral production, that's why obligatory to systemic antivirals in adequate doses.

Financial Disclosure:

None